Disease duration and disability in dysfeRlinopathy can be described by muscle imaging using heatmaps and random forests

ABSTRACT Introduction: The manner in which imaging patterns change over the disease course and with increasing disability in dysferlinopathy is not fully understood. Methods: Fibroadipose infiltration of 61 muscles was scored based on whole‐body MRI of 33 patients with dysferlinopathy and represente...

Full description

Saved in:
Bibliographic Details
Published inMuscle & nerve Vol. 59; no. 4; pp. 436 - 444
Main Authors Gómez‐Andrés, David, Díaz, Jorge, Munell, Francina, Sánchez‐Montáñez, Ángel, Pulido‐Valdeolivas, Irene, Suazo, Lionel, Garrido, Cristián, Quijano‐Roy, Susana, Bevilacqua, Jorge A.
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.04.2019
Subjects
Online AccessGet full text
ISSN0148-639X
1097-4598
1097-4598
DOI10.1002/mus.26403

Cover

More Information
Summary:ABSTRACT Introduction: The manner in which imaging patterns change over the disease course and with increasing disability in dysferlinopathy is not fully understood. Methods: Fibroadipose infiltration of 61 muscles was scored based on whole‐body MRI of 33 patients with dysferlinopathy and represented in a heatmap. We trained random forests to predict disease duration, Motor Function Measure dimension 1 (MFM‐D1), and modified Rankin scale (MRS) score based on muscle scoring and selected the most important muscle for predictions. Results: The heatmap delineated positive and negative fingerprints in dysferlinopathy. Disease duration was related to infiltration of infraspinatus, teres major–minor, and supraspinatus muscles. MFM‐D1 decreased with higher infiltration of teres major–minor, triceps, and sartorius. MRS related to infiltration of vastus medialis, gracilis, infraspinatus, and sartorius. Discussion: Dysferlinopathy shows a recognizable muscle MRI pattern. Fibroadipose infiltration in specific muscles of the thigh and the upper limb appears to be an important marker for disease progression. Muscle Nerve 59:436–444, 2019
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0148-639X
1097-4598
1097-4598
DOI:10.1002/mus.26403